Medcomtech, S.A.: peers
Medcomtech, S.A. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Medcomtech, S.A., Labiana Health, S.A., Vytrus Biotech, S.A., ADL Bionatur Solutions, Euroespes S.A., EuKedos S.p.A., Icecure Medical Ltd, Lisata Therapeutics, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Medcomtech, S.A.base MED.MC · 🇪🇸 ES Percentile in Healthcare Percentile in Spain | Labiana Health, S.A. LAB.MC · 🇪🇸 ES Percentile in Healthcare Percentile in Spain | Vytrus Biotech, S.A. VYT.MC · 🇪🇸 ES Percentile in Healthcare Percentile in Spain | ADL Bionatur Solutions 041.SG · 🇪🇸 ES Percentile in Healthcare Percentile in Spain | Euroespes S.A. EEP.MC · 🇪🇸 ES Percentile in Healthcare Percentile in Spain | EuKedos S.p.A. EUK.MI · 🇮🇹 IT Percentile in Healthcare Percentile in Italy | Icecure Medical Ltd ICCM · 🇮🇱 IL Percentile in Healthcare Percentile in Israel | Lisata Therapeutics, Inc. LSTA · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $10 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one4th of 8 | $9 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one7th of 8 | $14 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one3rd of 8 | $23 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one2nd of 8 | $4 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one8th of 8 | $24 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one1st of 8 | $10 MAug 1, 2026 · Market data4th of 8 | $10 MAug 1, 2026 · Market data4th of 8 | $10 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | —— | —— | —— | —— | $60 MFY2025 · ESEF1st of 3 | $3 MFY2025 · SEC2nd of 3 | $0 MFY2025 · SEC3rd of 3 | $3 M3 ranked |
| Net income (Higher is better) | —— | —— | —— | —— | —— | $-1 MFY2025 · ESEF1st of 3 | $-15 MFY2025 · SEC2nd of 3 | $-17 MFY2025 · SEC3rd of 3 | $-15 M3 ranked |
| Employees (Better neither way: ranked highest first) | —— | —— | —— | —— | —— | —— | 67December 31, 2025 · Profileonly one with it | —— | 67— |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | ———— | ———— | ———— | ———— | +6.7%FY2025 · ESEF1st of 242nd50th | +2.7%FY2025 · SEC2nd of 232nd26th | ———— | +4.7%2 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | +3.1%FY2025 · SEConly one with it37th35th | ———— | +3.1%— |
| Earnings per share growth (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | -20.0%FY2025 · SEConly one with it21st37th | ———— | -20.0%— |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | ———— | ———— | ———— | ———— | 21.1%FY2025 · ESEF2nd of 210th30th | 36.4%FY2025 · SEC1st of 222nd43rd | ———— | 28.7%2 ranked |
| Operating margin (Higher is better) | ———— | ———— | ———— | ———— | ———— | 10.2%FY2025 · ESEF1st of 273rd59th | -446.4%FY2025 · SEC2nd of 27th14th | ———— | -218.1%2 ranked |
| Net margin (Higher is better) | ———— | ———— | ———— | ———— | ———— | -1.4%FY2025 · ESEF1st of 258th10th | -445.6%FY2025 · SEC2nd of 26th11th | ———— | -223.5%2 ranked |
| Free cash flow margin (Higher is better) | ———— | ———— | ———— | ———— | ———— | 0.8%FY2025 · ESEF1st of 254th16th | -432.3%FY2025 · SEC2nd of 27th8th | ———— | -215.7%2 ranked |
| Return on equity (Higher is better) | ———— | ———— | ———— | ———— | ———— | -2.6%FY2025 · ESEF1st of 371st14th | -188.8%FY2025 · SEC3rd of 312th7th | -74.7%FY2025 · SEC2nd of 332nd14th | -74.7%3 ranked |
| Valuation | |||||||||
| Price to sales (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | ———— | ———— | 3.0׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 58.8׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | —— |
| Price to book (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | ———— | ———— | 1.1׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 0.7׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | —— |
| Free cash flow yield (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | -146.1%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | -159.8%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | —— |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | ———— | ———— | ———— | ———— | 0.0×FY2025 · SEConly one with it5th7th | ———— | 0.0×— |
| Piotroski F-score (Higher is better) | —— | —— | —— | —— | —— | —— | 4 of 9FY2025 · SEConly one with it | —— | 4.0 of 9— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | —— | —— | —— | —— | 2 of 5FY2025 · Scorecard1st of 3 | 6 of 17FY2025 · Scorecard2nd of 3 | 1 of 9FY2025 · Scorecard3rd of 3 | 35% passed3 ranked |
| Growth checks (Higher is better) | —— | —— | —— | —— | —— | 1 of 2FY2025 · Scorecard1st of 3 | 2 of 6FY2025 · Scorecard2nd of 3 | 0 of 2FY2025 · Scorecard3rd of 3 | 33% passed3 ranked |
| Profitability checks (Higher is better) | —— | —— | —— | —— | —— | 1 of 3FY2025 · Scorecard1st of 3 | 1 of 5FY2025 · Scorecard2nd of 3 | 0 of 3FY2025 · Scorecard3rd of 3 | 20% passed3 ranked |
| Financial health checks (Higher is better) | —— | —— | —— | —— | —— | —— | 3 of 5FY2025 · Scorecard1st of 2 | 1 of 3FY2025 · Scorecard2nd of 2 | 47% passed2 ranked |
| Shareholder returns checks (Higher is better) | —— | —— | —— | —— | —— | —— | 0 of 1FY2025 · Scorecard1st of 2 | 0 of 1FY2025 · Scorecard1st of 2 | 0% passed2 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | —— | —— | —— | —— | —— | 11.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 2 | 58.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 2 | 34.7%2 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | —— | —— | —— | —— | —— | 122026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 2 | 392026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 2 | 262 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | —— | —— | —— | —— | —— | —— | +0.5 pp2026-Q2 against 2026-Q1 · 13Fonly one with it | +0.5 pp— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Medcomtech, S.A.: How market caps are worked out; Labiana Health, S.A.: How market caps are worked out; Vytrus Biotech, S.A.: How market caps are worked out; ADL Bionatur Solutions: How market caps are worked out; Euroespes S.A.: How market caps are worked out; EuKedos S.p.A.: How market caps are worked out; Icecure Medical Ltd: How market caps are worked out; Lisata Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Medcomtech, S.A. | — | — | — |
| Labiana Health, S.A. | — | — | — |
| Vytrus Biotech, S.A. | — | — | — |
| ADL Bionatur Solutions | — | — | — |
| Euroespes S.A. | — | — | — |
| EuKedos S.p.A. | 10.2%FY2025 | 73rd percentile in Healthcaremedian -7.7%, 674 companies | 59th percentile in Italymedian 8.8%, 101 companies |
| Icecure Medical Ltd | -446.4%FY2025 | 7th percentile in Healthcaremedian -7.7%, 674 companies | 14th percentile in Israelmedian -0.2%, 67 companies |
| Lisata Therapeutics, Inc. | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Medcomtech, S.A. | Labiana Health, S.A. | Vytrus Biotech, S.A. | ADL Bionatur Solutions | Euroespes S.A. | EuKedos S.p.A. | Icecure Medical Ltd | Lisata Therapeutics, Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | — | — | — | — | $60 MESEF1st | $3 MSEC2nd | $0 MSEC3rd |
| 2024 | — | — | — | — | — | $56 MESEF1st | $3 MSEC2nd | $1 MSEC3rd |
| 2023 | — | — | — | — | — | — | $3 MSEC | — |
| 2022 | — | — | — | — | — | — | $3 MSEC | — |
| 2021 | — | — | — | — | — | — | $4 MSEC | — |
| 2020 | — | — | — | — | — | — | $4 MSEC | — |
| 2019 | — | — | — | — | — | — | $2 MSEC | — |
| 2016 | — | — | — | — | — | — | — | $35 MSEC |
| 2015 | — | — | — | — | — | — | — | $22 MSEC |
| 2014 | — | — | — | — | — | — | — | $18 MSEC |
| 2013 | — | — | — | — | — | — | — | $15 MSEC |
| 2012 | — | — | — | — | — | — | — | $14 MSEC |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Medcomtech, S.A.#
Companies of the same industry first, then the same sector, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Labiana Health, S.A.LAB.MC · 🇪🇸 SpainSame sector: Healthcare · Similar size: $9 M market cap against $10 M · Same country: SpainMarket cap $9 M (last known, Jan 5, 2024)69 of 100 (industry or sector 25 + size 29 + country 15)In the group
- Vytrus Biotech, S.A.VYT.MC · 🇪🇸 SpainSame sector: Healthcare · Similar size: $14 M market cap against $10 M · Same country: SpainMarket cap $14 M (last known, Jan 5, 2024)68 of 100 (industry or sector 25 + size 28 + country 15)In the group
- ADL Bionatur Solutions041.SG · 🇪🇸 SpainSame sector: Healthcare (Biotechnology) · Similar size: $23 M market cap against $10 M · Same country: SpainMarket cap $23 M (last known, Jul 30, 2023)65 of 100 (industry or sector 25 + size 25 + country 15)In the group
- Euroespes S.A.EEP.MC · 🇪🇸 SpainSame sector: Healthcare (Diagnostics and Research) · Similar size: $4 M market cap against $10 M · Same country: SpainMarket cap $4 M (last known, Jul 30, 2023)64 of 100 (industry or sector 25 + size 24 + country 15)In the group
- EuKedos S.p.A.EUK.MI · 🇮🇹 ItalySame sector: Healthcare (Medical Care Facilities) · Similar size: $24 M market cap against $10 M · Same region: Southern Europe · Ratios of the last two fiscal years on fileMarket cap $24 M (last known, Jan 5, 2024) · revenue $60 M (year to December 2025)61 of 100 (industry or sector 25 + size 24 + country 7 + figures on file 5)In the group
- Icecure Medical LtdICCM · 🇮🇱 IsraelSame sector: Healthcare (Medical Care Facilities) · Similar size: $10 M market cap against $10 M · Ratios of the last two fiscal years on fileMarket cap $10 M (Aug 1, 2026) · revenue $3 M (year to December 2025)60 of 100 (industry or sector 25 + size 30 + figures on file 5)In the group
- Lisata Therapeutics, Inc.LSTA · 🇺🇸 USASame sector: Healthcare (Biotechnology) · Similar size: $10 M market cap against $10 M · Ratios of the last two fiscal years on fileMarket cap $10 M (Aug 1, 2026) · revenue $0 M (year to December 2025)60 of 100 (industry or sector 25 + size 30 + figures on file 5)In the group
- ADM Tronics Unlimited Inc.ADMT · 🇺🇸 USASame sector: Healthcare (Medical Devices) · Similar size: $10 M market cap against $10 M · Ratios of the last two fiscal years on fileMarket cap $10 M (last known, Jul 30, 2023) · revenue $3 M (year to March 2026)60 of 100 (industry or sector 25 + size 30 + figures on file 5)+ Add
- Immunovia AB (publ)IMMNOV.ST · 🇸🇪 SwedenSame sector: Healthcare (Diagnostics and Research) · Similar size: $10 M market cap against $10 M · Ratios of the last two fiscal years on fileMarket cap $10 M (last known, Jan 5, 2024) · revenue $0 M (year to December 2025)60 of 100 (industry or sector 25 + size 30 + figures on file 5)+ Add
- American Shared Hospital ServicesAMS · 🇺🇸 USASame sector: Healthcare (Medical Care Facilities) · Similar size: $10 M market cap against $10 M · Ratios of the last two fiscal years on fileMarket cap $10 M (Aug 1, 2026) · revenue $28 M (year to December 2025)60 of 100 (industry or sector 25 + size 30 + figures on file 5)+ Add
- Tempest Therapeutics, Inc.TPST · 🇺🇸 USASame sector: Healthcare (Biotechnology) · Similar size: $10 M market cap against $10 M · Ratios of the last two fiscal years on fileMarket cap $10 M (Oct 27, 2026)60 of 100 (industry or sector 25 + size 30 + figures on file 5)+ Add
- Bonk, Inc.BNKK · 🇺🇸 USASame sector: Healthcare (Pharmaceutical) · Similar size: $10 M market cap against $10 M · Ratios of the last two fiscal years on fileMarket cap $10 M (Oct 30, 2026) · revenue $2 M (year to December 2025)60 of 100 (industry or sector 25 + size 30 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.